Galapagos was proud to be a sponsor of United European Gastroenterology (UEG) Week 2022, one of the biggest events in the gastroenterology calendar!
Through various expert-led educational meetings and resources, Galapagos aim to support healthcare professionals with the insights and practical advice needed to optimise the care of patients with IBD.
Galapagos are committed to improving patients’ lives worldwide by targeting diseases with high unmet needs, such as IBD. Our mission is to develop transformational medicines by combining internal with external science with the goal to add years of life and to improve the quality of life for patients across the globe. Our focus and commitment to patients will always remain at the centre of everything we do.
Assessment of histological remission in patients treated with filgotinib by different scores and concordance with endoscopic and health-related quality of life outcomes: post hoc analysis from the SELECTION study
Use of faecal calprotection as a prognostic marker of response to treatment with filgotinib: post hoc analysis from the SELECTION study
Predictors of response to filgotinib in ulcerative colitis: post hoc analysis from the SELECTION study
Exploratory analysis of filgotinib safety data in a selected population of patiewnts with rheumatoid arthritis data from FINCH 1-4 and DARWIN 1-3 studies in perspective to integrated ulcerative colitis safety data
Trajectory modelling to indentify different types of individual response to therapy a post hoc analysis from the SELECTION study